Osteopetrosis is a fascinating, inherited polygenic disorder of bone metabolism characterized by a generalized increase in bone mass due to decreased bone resorption (1). While it is relatively rare, it provides important clues to the understanding of bone cell biology and the pathogenesis of metabolic bone diseases. Since osteopetrosis results from decreased osteoclastic bone resorption, its molecular and cellular etiology is intriguing with respect to the pathogenesis of osteoporosis, which is generally characterized by increased osteoclastic bone resorption. Thus, identification of the defects leading to osteopetrosis may allow design of a causative, cell biology-based therapeutic approach for osteoporosis.

Thus far, most animal models of osteopetrosis have been the result of spontaneous or experimental deletion of cytokines required for osteoclastogenesis, such as osteoprotegerin ligand (2, 3), macrophage colony-stimulating factor (4), or their respective down-stream signaling molecules, including NF-κB (5), PU.1 (6) and c-fos (7, 8). These associated phenotypes are due to the disruption of osteoclast differentiation from pluripotent osteoclast precursor cells, and are variably combined with hematological or immunological abnormalities, indicating the pleiotropic nature of these cytokines.

Saftig and associates (9) have now identified cathepsin K-deficiency as yet another cause for osteopetrosis. Cathepsin K, a member of the papain–cysteine protease family, is an enzyme that is abundantly and selectively produced by osteoclasts. Its major effects in the process of osteoclastic bone resorption include degradation of the bone matrix proteins osteopontin, osteonectin and collagen types I and II at an acidic pH. A mutation of the human cathepsin K gene has recently been linked to human pycnodysostosis, which is an osteopetrotic disorder of variable severity and associated abnormalities, including short stature, dysplasia of membranous bones (clavicle, skull) and acroosteolysis of the distal phalanges (10).

Analysis of cathepsin K knock-out mice revealed viable and fertile offspring without obvious malformations or abnormalities until the age of 10 months (9). The most striking feature in homozygous littersmates was the presence of dense, thick trabeculae, which were most prevalent in rapidly growing areas of endochondral ossification and spared the membranous bone areas, as assessed by radiological analysis. Scanning electron microscopy revealed the retention of cancellous bone and the presence of thick trabeculae in cathepsin K-deficient mice. Histological studies confirmed these findings and showed that marrow cavities contained large amounts of primary unresorbed spongiosa; however, hematopoiesis was normal in cathepsin K-deficient mice, which is in contrast to other animal models of osteopetrosis. Of note, cathepsin K-deficient mice had intact epiphyseal and vertebral growth plates and normal longitudinal bone growth (9). Ultrastructural analysis of cathepsin K-deficient osteoclasts revealed signs of decreased proteolytic activity. Finally, cathepsin K-deficient osteoclasts, when tested for their functional activity on dentine slices, produced fewer resorption pits with a lower pit volume and depth compared with wild-type osteoclasts (9). Collectively, these data clearly confirm that cathepsin K is essential for osteoclastic resorption of bone matrix.

In contrast to other forms of osteopetrosis, which are due to disrupted osteoclastogenesis, cathepsin K-deficiency is associated with an inhibition of osteoclast activity. Similar effects have also been reported for targeted ablation of proto-oncogenes such as c-src (11, 12) and c-cbl (13). As a result of high and specific osteoclastic expression, cathepsin K deficiency specifically targets osteoclasts while not interfering with immune cell function or hematopoiesis. Conceptually, it therefore seems possible to use cathepsin K protease inhibitors to inhibit increased osteoclastic activity in patients with osteoporosis due to glucocorticoid excess, estrogen deficiency, rheumatoid arthritis or hypercalcemia of malignancy. Clinical studies will tell us more…

References